TScan Therapeutics (TCRX) EBIT Growth (1y) (2021 - 2026)
TScan Therapeutics (TCRX) EBIT Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.14% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 269.85% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1,528.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -336.63% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 99.51% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -36.55% |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.11% |
| Mar 31, 2026 | 19.62% |
| Dec 31, 2025 | 35.01% |
| Sep 30, 2025 | -13.58% |
| Jun 30, 2025 | -13.31% |
| Mar 31, 2025 | -15.55% |
| Dec 31, 2024 | -71.90% |
| Sep 30, 2024 | -31.82% |
| Jun 30, 2024 | -38.62% |
| Mar 31, 2024 | -37.95% |
| Dec 31, 2023 | -14.52% |
| Sep 30, 2023 | -49.28% |
| Jun 30, 2023 | -61.42% |
| Mar 31, 2023 | -40.71% |
| Dec 31, 2022 | -31.31% |
| Sep 30, 2022 | -4.65% |
| Jun 30, 2022 | -42.77% |
| Mar 31, 2022 | -104.13% |
| Dec 31, 2021 | -81.84% |
| Sep 30, 2021 | -120.92% |